Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Sarilumab on Patient-reported Outcomes in Patients With Moderately to Severely Active Rheumatoid Arthritis and With Inadequate Response or Intolerance to Current Conventional Synthetic DMARDs or Tumor Necrosis Factor Inhibitors

NCT03449758 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT03449758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03449758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Sarilumab on Patient-reported Outcomes in Patients With Moderately to Severely Active Rheumatoid Arthritis and With Inadequate Response or Intolerance to Current Conventional Synthetic DMARDs or Tumor Necrosis Factor Inhibitors
Lead sponsor
Sanofi
Phase
Phase 4
Overall status
Completed
Start date
March 5, 2018
Completion date
July 31, 2019
Enrollment
84 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis